about
Glucose metabolism in gastric cancer: The cutting-edgeHyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer.Solitary fibrous tumor of the greater omentum, mimicking gastrointestinal stromal tumor of the small intestine: a case report.Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradicationNon-exposed endoscopic wall-inversion surgery as a novel partial gastrectomy technique.Possible associations of rectal carcinoma with Schistosoma japonicum infection and membranous nephropathy: a case report with a review.Palliative distal gastrectomy offers no survival benefit over gastrojejunostomy for gastric cancer with outlet obstruction: retrospective analysis of an 11-year experience.Safety and Effectiveness of Endovenous Laser Ablation Combined With Ligation for Severe Saphenous Varicose Veins in Japanese Patients.Evaluation of 18F-FDG uptake for detecting lymph node metastasis of gastric cancer: a prospective pilot study for one-to-one comparison of radiation dose and pathological findings.Feasibility of laparoscopic gastrectomy for elderly gastric cancer patients: meta-analysis of non-randomized controlled studies.Short-term outcomes of robotic radical esophagectomy for esophageal cancer by a nontransthoracic approach compared with conventional transthoracic surgery.Poorly differentiated mesenteric carcinoma of unknown primary site detected by abscess formation: case report.Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.Comparison of Prognostic Abilities Among Preoperative Laboratory Data Indices in Patients with Resectable Gastric and Esophagogastric Junction Adenocarcinoma.Results of a nationwide questionnaire-based survey on nutrition management following gastric cancer resection in Japan.Gastric Cancer With Primitive Enterocyte Phenotype: An Aggressive Subgroup of Intestinal-type Adenocarcinoma.Updated evidence on endoscopic resection of early gastric cancer from Japan.Re-evaluating the prognostic validity of the negative to positive lymph node ratio in node-positive gastric cancer patients.Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.Increasing the Number of Examined Lymph Nodes is a Prerequisite for Improvement in the Accurate Evaluation of Overall Survival of Node-Negative Gastric Cancer Patients.Lymphogenous metastasis to the transverse colon that originated from signet-ring cell gastric cancer: A case report and review of the literature.Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.Short-term exposure to a 1439-MHz TDMA signal exerts no estrogenic effect in rats.Early endoscopic management for early bowel obstruction after gastrectomy: a case report.Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2.A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model.Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor.In Epstein-Barr virus-associated gastric carcinoma a high density of CD66b-positive tumor-associated neutrophils is associated with intestinal-type histology and low frequency of lymph node metastasis.Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells.Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer.Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation.Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications.Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells.Radical esophagectomy for a 92-year-old woman with granulocyte colony-stimulating factor-producing esophageal squamous cell carcinoma: a case report.S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis.Analysis of glycero-lysophospholipids in gastric cancerous ascites.The suppressive effect of sphingosine 1-phosphate on monocyte-endothelium adhesion may be mediated by the rearrangement of the endothelial integrins alpha(5)beta(1) and alpha(v)beta(3).Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.Complete coverage of in situ aortograft by total omental pedicle flap as the most reliable treatment of aortoesophageal fistula.Systemic inflammatory response in gastric cancer.
P50
Q26766098-C9BDA137-A7F7-4C19-96BF-628BEBE08E8EQ33245405-8BC565E7-E343-4F6B-B130-296D0FDB8F63Q33423112-11E0A62C-1A4B-4C75-B088-F8361C150327Q33621793-8D4E19C0-3102-4514-998B-6FCE2AF6C868Q33810637-1B3A82EC-EE12-4357-98C6-25A45DC85F40Q33839874-AD168557-CFFA-4CC2-97EE-6B7B50956278Q35189549-CAF13713-1DE1-45B6-B61C-DDBF33FA9F39Q35888348-69313B3F-FC90-4622-BC91-89F657501512Q36340775-B63A4A4A-5373-492A-9B69-0C4BA14037F2Q36344692-8E5D2104-A5F8-4E14-B948-0B7D5776259AQ37461934-D030D96B-463D-4F94-9B73-16477EE091C5Q37497305-29381F68-83AA-4598-B571-E86B7E803F9CQ37703392-904E3310-BB28-45AE-A219-42F002FCC71DQ38663037-06705E1D-639A-4739-8ED2-36027F818792Q38732950-74ACA235-F7FA-4D74-BE27-53AA17B10410Q38785954-91332A6F-2721-4151-9C8B-0782F3D96B2FQ38972448-78F99031-2DAC-43F5-8FC1-66EC80F4BBE6Q39006825-04A2BE28-F6D2-4FF4-BF46-E24F0C0E46ABQ39233917-99EFA233-278D-420E-891A-33105EC5775CQ39259766-28A5A041-8FCE-47CC-A6B4-36FDD65A417BQ39318824-16E044D0-D1C8-41F2-86F1-2BD9089EC146Q39377073-F58852A9-EB59-4A11-83CB-93394E2C5291Q39940734-532EA16E-32AE-4680-85D7-2321C1B74C21Q40100091-784EFDC8-123D-4CCA-A32F-E6F68D48A0B8Q40141205-65531565-6A1D-4707-BC8C-6820105F0852Q40168565-6B2F1E26-C2FE-4428-A763-6E04498879C2Q40350899-934B64DD-473B-41DF-B032-55A7703A23E6Q40355282-497AA023-8A91-4604-9CE2-2815AF5DD1E1Q40359909-16C7DB89-0F3F-43FC-8515-3B0FABBC1FDAQ40365328-86810480-2FDB-463E-BE5D-A9A32059FC3CQ40369241-2C7109DE-84AE-4437-8C4B-A49B28994389Q40416586-A1F01126-A0FB-4C40-AE07-A0187C85C6CCQ40489621-AAF86C95-9598-4370-A0CF-62E0327A4BB0Q41465672-95A26FAB-7E3C-4E6C-B538-EB946BF40507Q42263964-1A5882E9-C987-430A-941F-1E994E65104BQ42278873-FC96CEF7-0CB2-4086-84D4-434AB5776EDBQ42510506-C5F27FA6-E841-476B-B678-C5E5FCA6DD4CQ43144591-3AB6C2DC-5304-4E5F-915E-D017DD9D5474Q44244332-FB5341E4-48CC-419B-8520-D41925931D1FQ44284760-B56FEDAE-4B18-4ACC-A6EA-6374FEC5CBCA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hiroharu Yamashita
@ast
Hiroharu Yamashita
@en
Hiroharu Yamashita
@es
Hiroharu Yamashita
@sl
type
label
Hiroharu Yamashita
@ast
Hiroharu Yamashita
@en
Hiroharu Yamashita
@es
Hiroharu Yamashita
@sl
prefLabel
Hiroharu Yamashita
@ast
Hiroharu Yamashita
@en
Hiroharu Yamashita
@es
Hiroharu Yamashita
@sl
P1053
E-7058-2011
P106
P31
P3829
P496
0000-0002-9468-3716